CTA
AIMT

Carillon Tower Advisers’s Aimmune Therapeutics AIMT Stock Holding History

Carillon Tower Advisers’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-964,906
Closed -$20.1M – 517
2019
Q2 		$20.1M Hold
964,906
– – 0.14% 253
2019
Q1 		$21.6M Hold
964,906
– – 0.15% 230
2018
Q4 		$23.1M Hold
964,906
– – 0.2% 200
2018
Q3 		$26.3M Hold
964,906
– – 0.19% 191
2018
Q2 		$25.9M Hold
964,906
– – 0.2% 178
2018
Q1 		$28.6M Sell
964,906
-590,828
-38% -$20.8M 0.22% 159
2017
Q4 		$58.8K Buy
+1,555,734
New +$50.2M 0.63% 37

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Carillon Tower Advisers's AIMT Position: Q3 2019 in Review

Carillon Tower Advisers sold out of Aimmune Therapeutics (AIMT) in Q3 2019, closing a stake of 964,906 shares — an estimated $20.1M sold.

Carillon Tower Advisers first reported a position in AIMT in Q4 2017 and held it in 7 quarters. The position peaked at $28.6M in Q1 2018. 146 funds tracked by Wall St. Rank hold AIMT as of Q3 2019.

  • Carillon Tower Advisers reported no remaining Aimmune Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Carillon Tower Advisers sold 964,906 Aimmune Therapeutics shares in Q3 2019, an estimated $20.1M.
  • Carillon Tower Advisers first reported a position in Aimmune Therapeutics in Q4 2017 and held it in 7 quarters.
  • Carillon Tower Advisers's Aimmune Therapeutics position peaked at $28.6M in Q1 2018.
  • 146 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2019.

Based on Carillon Tower Advisers's 13F filing for Q3 2019, filed 5 Nov 2019.